Abstract Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to
the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or …

Understanding immunity in humans to Group A Streptococcus (Strep A) is critical for the
development of successful vaccines to prevent the morbidity and mortality attributed to Strep …

The age of children with pleural empyema with confirmed GAS infection ranged from 10
months to 11 years (median 3 [IQR 1· 6–5] years); nine (56%) of the 16 cases were in boys …

The high strain diversity of Streptococcus pyogenes serves as a major obstacle to vaccine
development against this leading global pathogen. We did a systematic review of studies in …

Group A Streptococcus (GAS) is a ubiquitous pathogen that causes a wide spectrum of
human diseases. These include mild conditions such as tonsillitis and impetigo (with over …

Streptococcus pyogenes causes at least 750 million infections and more than 500,000
deaths each year. No vaccine is currently available for S. pyogenes and the use of human …

Background Few studies have assessed participant safety in human challenge trials (HCTs).
Key questions regarding HCTs include how risky such trials have been, how often adverse …

Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that
causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and …

Background Public health guidance recommending isolation of individuals with group A
streptococcal (GAS) infection or carriage for 12–24 h from antibiotic initiation to prevent …

Probiotic supplements are suggested to promote human health by preventing pathogen
colonization. However, the mechanistic bases for their efficacy in vivo are largely …